Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10152
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNorman, Trevor Ren
dc.date.accessioned2015-05-15T23:30:46Z
dc.date.available2015-05-15T23:30:46Z
dc.date.issued2006-05-01en
dc.identifier.citationThe Australian and New Zealand Journal of Psychiatry; 40(5): 394-401en
dc.identifier.govdoc16683964en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10152en
dc.description.abstractAntidepressant drugs represent the principal form of treatment for major depressive disorder. While there are a plethora of medications available for this task, current drugs have many shortcomings. In the face of these deficiencies there is an ongoing search for new agents. The search has been guided, in part, by drug design based on existing agents and their putative mechanism of action. This has been less than fruitful in addressing inadequacies of existing medications as it has not produced compounds which are novel in terms of pharmacological mechanisms. Recent insights from molecular biological approaches hold promise for the discovery of novel compounds, in particular the so-called neurogenesis hypothesis suggests novel therapeutic approaches. Although significantly modified over the years, the monoamine hypothesis of depression and antidepressant drug action still remains an important driving force behind the development of new compounds. Several recently marketed agents and some in early-phase development tend to conform to these existing mechanistic hypotheses. Clearly the place of these agents in the treatment of depression is dependent on issues such as short- and long-term safety and efficacy. Duloxetine has been developed as a dual monoamine re-uptake inhibitor. Agomelatine is a compound with major effects on the circadian system as well as effects on subtypes of the serotonin receptor system. While the mechanism of action of this compound is not certain, recent evidence would suggest that the drug exerts its effects through antagonist actions at serotonin receptors. Compounds based on the hypothalamic pituitary adrenal axis, substance P antagonism and other neuropeptides have potential application for the treatment of depression but require further development before that potential is realized.en
dc.language.isoenen
dc.subject.otherAcetamides.therapeutic useen
dc.subject.otherDepressive Disorder, Major.drug therapy.metabolism.psychologyen
dc.subject.otherHumansen
dc.subject.otherHypnotics and Sedatives.therapeutic useen
dc.subject.otherNerve Growth Factors.metabolismen
dc.subject.otherSerotonin Uptake Inhibitors.therapeutic useen
dc.subject.otherSubstance P.metabolismen
dc.subject.otherThiophenes.therapeutic useen
dc.subject.otherVasopressins.metabolismen
dc.titleProspects for the treatment of depression.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Australian and New Zealand Journal of Psychiatryen
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1111/j.1440-1614.2006.01814.xen
dc.description.pages394-401en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16683964en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptPsychiatry (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Feb 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.